Lipopeptide Nanoparticles for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral nucleic acid delivery methods, such as lipid-nucleic acid nanoparticle complexes, face limitations in efficiency and toxicity, particularly concerning long-term use due to innate immune activation and low degradation/clearance, necessitating the development of alternative agents for effective and safe delivery of therapeutic nucleic acids to target cells.
Innovation Solution
The use of cationic lipopeptides, like stearoyl-Cys-His-His-Lys-Lys, which self-assemble with nucleic acids to form complexes with a neutral or negative surface charge, reducing toxicity and improving biodistribution by eliminating the need for organic solvents and incorporating polymeric charge-neutralizing agents like PEGylated lipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids are used to form lipid nanoparticles for nucleic acid delivery, then transfection efficiency is improved, but toxicity increases due to innate immune activation and low degradation over long-term use
Solution Approach 1:
The patent changes the chemical composition parameters of the delivery particle by replacing cationic lipids with cationic lipopeptides. This parameter change maintains the cationic charge necessary for nucleic acid complexation and transfection efficiency while altering the molecular structure to improve biocompatibility, reduce immune activation, and enhance degradation profiles for long-term safety
Solution Approach 2:
The patent employs composite materials by designing lipopeptide molecules that combine a lipid moiety (for membrane interaction and stability) with a peptide component (for biocompatibility and degradability). This composite structure integrates the advantages of both lipid and peptide materials to achieve effective transfection with reduced toxicity
2Stability of the object's composition
If polyethylene glycol is used to shield cationic particles, then biodistribution is improved, but electronic association with serum proteins increases leading to opsonisation and clearance
Solution Approach 1:
The patent changes the surface charge parameter by using self-assembled lipopeptide nanoparticles that inherently present a neutral or negative zeta potential at physiological pH, eliminating the need for PEG shielding. This parameter change prevents electronic association with negatively charged serum proteins, avoiding opsonisation while maintaining stable biodistribution
Solution Approach 2:
The patent extracts and eliminates the PEG component from the delivery system by using lipopeptide-based particles with appropriate surface charge characteristics. This removal of PEG simplifies the formulation while avoiding the adverse effects of PEG-associated opsonisation and clearance mechanisms
3Productivity
If large volume plasmid DNA solution is administered systemically, then nucleic acid delivery is achieved, but high pressure in blood vessels and extravasations occur
Solution Approach 1:
The patent applies phase transition principles by forming nucleic acids into self-assembled lipopeptide nanoparticle complexes. This phase transition from dissolved nucleic acid to particulate form enables delivery at much lower volumes and concentrations, eliminating blood vessel pressure issues while maintaining effective nucleic acid delivery to target cells
Solution Approach 2:
The patent uses self-assembled lipopeptide nanoparticle shells that encapsulate and protect the nucleic acid cargo. These flexible nanoparticle structures enable efficient cellular uptake and delivery without requiring large injection volumes, thereby avoiding vascular pressure and extravasation problems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the stability and transfection efficiency of nucleic acids, reduces toxicity, and improves biodistribution, enabling effective and sustained delivery of therapeutic nucleic acids, as demonstrated by higher gene expression levels and reduced immune activation compared to traditional methods.
Implementation Method 1
the peptide component will include amino acids such as lysine and arginine, which due to their strongly basic/positively charged properties, allow for the condensation of nucleic acid molecules such as plasmid DNA at physiological pH
Implementation Method 2
polyethylene glycol (PEG) has been used to 'shield' or neutralise the positive charges of the cationic particles
Data Source
AI summary
Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.